1. Home
  2. ZNTL vs OPRT Comparison

ZNTL vs OPRT Comparison

Compare ZNTL & OPRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZNTL
  • OPRT
  • Stock Information
  • Founded
  • ZNTL 2014
  • OPRT 2005
  • Country
  • ZNTL United States
  • OPRT United States
  • Employees
  • ZNTL N/A
  • OPRT N/A
  • Industry
  • ZNTL Biotechnology: Pharmaceutical Preparations
  • OPRT Finance: Consumer Services
  • Sector
  • ZNTL Health Care
  • OPRT Finance
  • Exchange
  • ZNTL Nasdaq
  • OPRT Nasdaq
  • Market Cap
  • ZNTL 134.7M
  • OPRT 146.4M
  • IPO Year
  • ZNTL 2020
  • OPRT 2019
  • Fundamental
  • Price
  • ZNTL $2.32
  • OPRT $7.89
  • Analyst Decision
  • ZNTL Buy
  • OPRT Buy
  • Analyst Count
  • ZNTL 8
  • OPRT 4
  • Target Price
  • ZNTL $8.53
  • OPRT $5.17
  • AVG Volume (30 Days)
  • ZNTL 2.7M
  • OPRT 810.8K
  • Earning Date
  • ZNTL 03-04-2025
  • OPRT 02-12-2025
  • Dividend Yield
  • ZNTL N/A
  • OPRT N/A
  • EPS Growth
  • ZNTL N/A
  • OPRT N/A
  • EPS
  • ZNTL N/A
  • OPRT N/A
  • Revenue
  • ZNTL $40,560,000.00
  • OPRT $763,600,000.00
  • Revenue This Year
  • ZNTL N/A
  • OPRT N/A
  • Revenue Next Year
  • ZNTL N/A
  • OPRT $8.34
  • P/E Ratio
  • ZNTL N/A
  • OPRT N/A
  • Revenue Growth
  • ZNTL N/A
  • OPRT N/A
  • 52 Week Low
  • ZNTL $1.61
  • OPRT $2.05
  • 52 Week High
  • ZNTL $18.07
  • OPRT $9.25
  • Technical
  • Relative Strength Index (RSI)
  • ZNTL 49.24
  • OPRT 77.71
  • Support Level
  • ZNTL $2.37
  • OPRT $5.43
  • Resistance Level
  • ZNTL $2.36
  • OPRT $9.25
  • Average True Range (ATR)
  • ZNTL 0.25
  • OPRT 0.71
  • MACD
  • ZNTL 0.08
  • OPRT 0.27
  • Stochastic Oscillator
  • ZNTL 69.27
  • OPRT 72.59

About ZNTL Zentalis Pharmaceuticals Inc.

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.

About OPRT Oportun Financial Corporation

Oportun Financial Corp is engaged in providing financial services to people who either do not have a credit score or who may have a limited credit history. The company offers Personal Loans, Auto Loans, unsecured personal loans, and secured personal loans, and provides deposit accounts, debit card services, and other transaction services to its customers. Its product offerings include small-dollar, unsecured installment loans and other products and services.

Share on Social Networks: